Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Trial Profile

Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Deferasirox (Primary) ; Deferoxamine (Primary)
  • Indications Anaemia; Aplastic anaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Pharmacodynamics
  • Acronyms BIOFER12
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 10 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 14 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top